Titre
Effects of gonadotropin-releasing hormone (GnRH) agonist on pituitary and ovarian responses to pulsatile GnRH therapy in polycystic ovarian disease
Type
article
Institution
Externe
Périodique
Auteur(s)
Surrey, E. S.
Auteure/Auteur
de Ziegler, D.
Auteure/Auteur
Lu, J. K.
Auteure/Auteur
Chang, R. J.
Auteure/Auteur
Judd, H. L.
Auteure/Auteur
Liens vers les personnes
ISSN
0015-0282
Statut éditorial
Publié
Date de publication
1989-10
Volume
52
Numéro
4
Première page
547
Dernière page/numéro d’article
52
Peer-reviewed
Oui
Notes
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Oct
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Oct
Résumé
Nine clomiphene citrate-resistant polycystic ovarian disease (PCOD) patients received intravenous gonadotropin-releasing hormone (GnRH) pulses before and immediately after 1 month of GnRH agonist (GnRH-a) therapy. Circulating gonadotropin and ovarian steroid levels, as well as follicular development, were measured throughout therapy. Results were compared with those obtained from five hypogonadotropic patients treated with GnRH pulses only who ovulated during six of seven treatment cycles. Only two PCOD patients ovulated normally with GnRH pulses before GnRH-a therapy. Aberrant gonadotropin and ovarian steroid secretory patterns were noted in the others. After GnRH-a, gonadotropin and ovarian steroid hormone levels were similar to those of the hypogonadotropic patients. Subsequent secretory responses to GnRH pulses were partially normalized. However, only two additional PCOD patients ovulated.
Sujets
PID Serval
serval:BIB_9F70EABF3396
PMID
Date de création
2008-02-28T10:37:21.427Z
Date de création dans IRIS
2025-05-21T04:20:04Z